[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-fatigue\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-fatigue":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,52,86,118,152],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":34,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100633163","mecfs-brain-fog-cognitive-rehabilitation-trial-100633163",false,"NCT07523113","ME\u002FCFS Brain Fog: Cognitive Rehabilitation Trial","Brain Training for Chronic, Post-viral, Brain Fog: Study A","Inclusion Criteria:\n\n* diagnosis of ME\u002FCFS that preceded cognitive complaints\n* mild or greater cognitive impairment\n* moderate or greater brain fog\n* some impairment in the performance of daily activities\n* ≥ 18 years, no upper limit if medically stable\n* reside in the community (as opposed to a hospital or skilled nursing facility)\n* able to travel to the laboratory on multiple occasions\n* has Internet service\n* has a personal computer, laptop, or tablet that can access the Internet\n* sufficiently fit, from both a physical and mental health perspective, to take part in the study\n* adequate sight and hearing to complete the UFOV test\n* adequate thinking skills, e.g., ability to follow directions and retain information to complete UFOV and CTAL, as marked by the judgement of the screener that the candidate is able to adequately complete the UFOV and CTAL\n* sufficient English proficiency (i.e., ability to speak, understand, read, and write to take part in study activities)\n\nExclusion Criteria:\n\n* cognitive impairment due to a developmental disability, psychiatric disorder, or substance abuse, or due to another type of brain injury, such as traumatic brain injury, stroke, or a progressive brain disease, such as Alzheimer's Dementia\n* current substance abuse disorder\n* diagnosis of postural orthostatic tachycardia syndrome (POTS) by a healthcare provider\n* prior cognitive processing speed training on DoubleDecision or a similar program\n* cannot tolerate taVNS\n* prior history of heart attack or other serious cardiac events\n* implanted medical device of any type\n* vasovagal syncope or history of fainting\n* history of seizures or epilepsy\n* temporomandibular Joint (TMJ) syndrome or other conditions that cause substantial jaw pain\n* history of peripheral nerve injury to the head, neck, or face\n* pregnant or breastfeeding\n* not able or willing to get an MRI scan\n* not able or willing to get a blood draw","ALL","18 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"NA","The purpose of this study is to compare two approaches to cognitive rehabilitation in adults with post-viral cognitive syndrome, which resulted in brain fog. All participants will be screened for eligibility prior to participation. Most of the procedures will take place over a phone call or secure telehealth platform (i.e., Zoom). However, participants will be asked to visit UAB on three occasions for blood sample collection and brain imaging (about 2 hours each). Online testing will happen one month before treatment, one day before treatment, one day afterwards, and 6 months afterwards. The study will utilize two different forms of rehabilitation training to improve participants' cognitive ability. Participants will be randomized to one of the two treatment groups. The first treatment approach, known as Constraint-Induced Cognitive Therapy (CICT), will feature (A) web-based computer \"games\" that trains how quickly individuals process information that they receive through their senses; (B) online training on everyday activities with important cognitive components, (C) procedures designed to transfer improvements in cognition from the treatment setting to everyday life, and (D) a non-invasive form of vagus nerve stimulation, also known as trans-auricular VNS (taVNS). The second approach, known as Brain Fitness Training (BFT), will include (A) web-based computer \"games\" that train reaction time and eye-hand coordination; (B) in-lab training on relaxation, breathing, healthy nutrition, and healthy sleep, (C) education about how relaxation, breathing, nutrition, and sleep are connected to thinking effectiveness, and (D) taVNS. Approximately 30 hours of training will be conducted over a secure telehealth platform (i.e., Zoom) in the span of two- to four- weeks. A typical CICT session will consist of one hour of gaming, with the bulk of the session being spent on cognitive training of the target behaviors and procedures designed to promote transfer of therapeutic gains to daily life. ta-VNS will be administered for 10 minutes before gaming and in-lab target behavior training. A typical BFT session will consist of one hour of gaming, training on healthy lifestyle behaviors (i.e., healthy sleep, nutrition, and relaxation habits), as well as procedures designed to promote transfer of behavior changes to daily life. Ta-VNS will be administered for 10 minutes before gaming and in-lab target behavior training. Training sessions in both conditions will be scheduled based on participants' availability, with the options for sessions scheduled to be as close as every weekday over 2 weeks or as loosely as every other weekday (i.e., over a 4-week span). If a caregiver is available, they will receive training on how to best support participants in their therapeutic program. After the training ends, both groups will receive 4 follow-up phone calls approximately one week apart to promote integration of the gained skills into everyday life. Outcomes measured will include cognitive processing speed, cognitive function on laboratory tests, and spontaneous performance of everyday activities with important cognitive components in daily life.",[26,27,28,29,30,31,32,33],"ME\u002FCFS","ME\u002FCFS Following EBV-associated Infectious Mononucleosis","ME\u002FCFS Following COVID-19","Chronic Fatigue","Chronic Fatigue Syndrome (CFS)","Brain Fog","Cognitive Impairment","Cognitive Dysfunction",[26,29,35,32,33,36,37,38],"Brain fog","post-viral syndrome","Cognitive Rehabilitation","CICT","NOT_YET_RECRUITING","2026-06-04",{"date":42,"type":43},"2026-06-08","ACTUAL",{"date":45,"type":20},"2026-06",{"date":47,"type":20},"2028-06",{"name":49,"class":50},"University of Alabama at Birmingham","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":21,"phases":63,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":4},"100639369","phase-2-modafinil-for-debilitating-fatigue-in-quiescent-inflammatory-bowel-disease-modifi-ibd-trial-100639369","NCT07582458","Modafinil for Debilitating Fatigue in Quiescent Inflammatory Bowel Disease MODIFI-IBD Trial)","Modafinil for Debilitating Fatigue in Quiescent Inflammatory Bowel Disease: a Multicentre,Randomised, Double-blind, Placebo-controlled, Clinical Trial (MODIFI-IBD Trial)","MODIFI-IBD","Inclusion Criteria:\n\n* Willing and able to provide signed informed consent at the screening visit as well as comply with all study visits and requirements through the end of the study\n* Age between 18 to 75 years at screening.\n* ≥1 year diagnosis of IBD, based on a combination of clinical, endoscopic, histologic and radiologic criteria\n* Chronic fatigue for at least six months\n* Severe fatigue as confirmed with a score of ≥11 on section I of the IBD-F\n* Clinically quiescent IBD with a Harvey Bradshaw Index (HBI) \\\u003C5 for CD patients or a Simple Colitis Clinical Activity Index (SCCAI) ≤2 for patients with UC or IBD-unclassified\n* Faecal calprotectin \\\u003C250 µg\u002Fg\n* Stable IBD medication for ≥3 months before screening visit and no change in IBD medication planned for ≥3 months\n\nExclusion Criteria:\n\n* Contraindications for the use of modafinil, such as:\n\n  * Uncontrolled hypertension\n  * Cardiac arrhythmia\n  * A history of left ventricular hypertrophy or cor pulmonale, and in patients with mitral valve prolapse who have previously developed mitral valve prolapse syn-drome during treatment with central nervous system stimulants\n  * Patients with hereditary galactose intolerance, lactase deficiency, glucose-galactose malabsorption\n* Patients using medication which interacts clinically significant with modafinil, see section 3.3 'Mechanism of action \\& Drug class'\n* Patients using pharmacological agents with similar effects to modafinil, like central nerv-ous system (CNS) stimulants or other wakefulness-promoting drugs such as methylphenidate and amphetamines\n* Surgery before or during study period that impacts ability to participate in this study, per investigator judgement\n* Participation in another intervention study (excl. registries and post marketing studies)\n* Pregnancy or nursing at the moment of screening or planned pregnancy within two months after last dose\n* People with a diagnosis of drug or alcohol dependence syndrome will be excluded\n* Comorbidities or confirmed diagnoses known to cause fatigue, which may influence study outcomes, including but not limited to:\n\n  * Anaemia (Hb \\\u003C7.0 mmol\u002Fl for women and \\\u003C8.0 mmol\u002Fl for men) and which is judged as clinically significant by the investigator\n  * Folate deficiency (\\\u003C6.0 nmol\u002Fl)\n  * Iron deficiency (ferritin \\\u003C20 g\u002Fl for women and \\\u003C25 g\u002FL for men)\n  * Vitamin B12 deficiency (\\\u003C148 pmol\u002Fl)\n  * Liver insufficiency defined by an ALT or AST \\>2x ULN or total bilirubin \\> 2 mg\u002FdL\n  * Renal insufficiency defined by an estimated glomerular filtration rate \\\u003C 45 mL\u002Fmin, calculated using the Chronic Kidney Disease-Epidemiology Collaboration equation and\u002For a serum creatinine \\>178 μmol\u002FL (2mg\u002FdL)\n  * Auto-immune disorders such as primary sclerosing cholangitis, rheumatoid ar-thritis, systemic lupus erythematosus or coeliac disease\n  * Uncontrolled or recently diagnosed depression\n  * Active suicidal ideation\n  * Bipolar disorder\n  * Schizophrenia or other psychotic disorders\n  * Other psychiatric disorders that may interfere with the study as judged by the investigators\n  * History or current anxiety or sleep disorders\n  * Substance dependence disorders (e.g. alcohol, cannabis, drugs)\n  * Evidence, history, or suspicion of infectious diseases that may interfere with the study as judged by the investigators\n  * Active Epstein-Barr virus or cytomegalovirus infection\n  * Endocrinological disorders such as uncontrolled diabetes mellitus, untreated hy-pothyroidism, hypoadrenalism or hypogonadism\n  * Neurological disorders such as multiple sclerosis, dementia, Parkinson's disease or myasthenia gravis\n  * Heart failure\n  * Chronic obstructive pulmonary disease\n  * Obstructive sleep apnoea\n  * Active malignancy (exception of malignancies adequately treated with resection for non-metastatic basal cell carcinoma)\n  * Long\u002Fpost-COVID\n* Patients who are not able to complete the Dutch questionnaires in an online form\n* Has a clinically significant concurrent disease or relevant laboratory abnormality or a history of illness or medical condition that in the investigator's opinion could confound the study results or increase the participant's risk by taking part in the study","75 Years",{"count":62,"type":20},60,[64,65],"PHASE2","PHASE3","The goal of this clinical trial is to learn if modafinil can treat severe fatigue in adults aged 18 to 75 years with quiescent inflammatory bowel disease (IBD). The main questions it aims to answer are:\n\nDoes modafinil reduce fatigue more effectively than placebo, as measured by the mean difference in section I of the IBD-F questionnaire at week 8? Is modafinil safe and well tolerated in patients with quiescent IBD and severe fatigue?\n\nResearchers will compare modafinil to placebo to see if modafinil improves fatigue outcomes.\n\nParticipants will:\n\nattend one screening visit including assessment of disease activity, blood tests, stool testing, and an ECG; take modafinil or placebo for 8 weeks, starting at 100 mg daily with possible dose increases based on response and tolerability; complete online questionnaires at baseline, week 4, week 8, and week 12 about fatigue, quality of life, sleep, mood, and work productivity; be contacted regularly during the treatment period to discuss effect and side effects of the study medication; complete an online effort-based decision-making task at baseline and week 8.",[68,29],"Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis)",[70,71,72,73,74,75,76],"Modafinil","Inflammatory bowel disease","Crohn","Colitis","Fatigue","Remission","Pharmacological","2026-05-19",{"date":79,"type":43},"2026-05-22",{"date":81,"type":20},"2026-06-01",{"date":83,"type":20},"2027-06",{"name":85,"class":50},"Radboud University Medical Center",{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":94,"conditions":95,"keywords":102,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":114,"locationsCount":117},"100618493","expanded-access-use-of-human-umbilical-cord-blood-regenecyte-infusion-in-patients-with-chronic-fatigue-of-post-covid-condition-100618493","NCT07332338","Expanded Access Use of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Chronic Fatigue of Post-COVID Condition","Expanded Access Use of Human Umbilical Cord Blood (REGENECYTE) Infusion for Patients With Post-COVID Condition","Inclusion Criteria:\n\n* Male or female aged ≥ 18\n* With post-COVID condition\n* Has had a recent (within 7 days) negative SARS-CoV-2 test (an approved PCR (polyermerase chain reaction) or antigen test)\n* Not eligible for participation in any ongoing clinical trials of post-COVID condition with REGENECYTE\n* Able to provide signed informed consent (by the subject or his\u002Fher legally authorized representative)\n* Is willing and able to participate in all aspects of the study, including completion of subjective evaluations, attendance at scheduled clinic visits, and compliance with all protocol requirements as evidenced by providing a written informed consent\n\nExclusion Criteria:\n\n* Neurological disorders prior to COVID-19 diagnosis\n* With pre-existing terminal illness\n* With known immune disease\n* Is pregnant or breastfeeding\n* Is currently participating in another investigational study or has been taking any other investigational product (IP) within the last 4 weeks before screening\n* Has received any vaccination within 3 weeks prior to the first IP infusion or planning to receive vaccination during the treatment period\n* Judged by the investigator to be not suitable for study participation, including but not limited to pre-existing chronic diseases\n* Under the conditions that may increase risk of complications based on the medical judgment of the investigator and the parameters","EXPANDED_ACCESS","REGENECYTE® (HPC, Cord Blood (Hematopoietic Progenitor Cell, Cord Blood)) for treatment in patients with post-COVID.",[96,97,98,99,29,100,101],"Post-COVID-19 Condition","Post-COVID Condition","Post-COVID Syndrome","Long COVID","Chronic Fatigue Symptoms","Fatigue Post Viral",[99,103,104,105,106,107,108,109],"Post-COVID syndrome","Post-COVID condition","Umbilical cord blood","REGENECYTE","Post-COVID fatigue","Chronic fatigue symptoms","Fatigue post viral","AVAILABLE","2026-03-18",{"date":113,"type":43},"2026-03-23",{"name":115,"class":116},"StemCyte, Inc.","INDUSTRY",2,{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":124,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":16,"minAge":126,"maxAge":127,"enrollmentInfo":128,"targetDuration":4,"studyType":21,"phases":130,"briefSummary":131,"conditions":132,"keywords":135,"overallStatus":140,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":151},"100467475","phase-2-ca-mg-butyrate-in-gwi-100467475","NCT05367245","Ca-Mg Butyrate in GWI","Microbiome Targeted Oral Butyrate Therapy in Gulf War Multisymptom Illness","Butyrate","Inclusion Criteria:\n\n* Gulf war era veteran deployed 40 and 70 years old, in good health by medical history prior to 1990 meeting GWI case definition of CDC and Kansas criteria and\n* currently have no exclusionary diagnoses (self- reported) that could reasonably explain the symptoms of their fatiguing illness. The severity of illness is moderate to severe, scoring less than 30 of 100 on the physical domain of VSF36 .\n\nExclusion Criteria:\n\n* Untreated schizophrenia,\n* Untreated bipolar disorder,\n* Untreated delusional disorders,\n* Untreated dementias of any type and\n* active alcoholism or drug abuse.\n* Medical conditions excluded include (i) organ failure, (ii) defined rheumatologic inflammatory disorders, and (iii) transplant.\n* Use of Butyrate in any form in the 3 months prior to study drug, medications that would impact gut motility, diarrhea, chronic pain, and immune function e.g., steroids, (Last 3 months)\n* immunosuppressive drugs or biologic response modifiers within 3 months of study entry will be used as exclusion criteria.\n* Pregnancy, or planned pregnancy in the next 6 months,\n* Body mass index more than 35\n* Specific diets that may have enhanced or enriched fiber or butyrogenic formulations (FODMAP)\n* Medications that could potentially impact immune function in the past one month will be excluded (e.g., steroids, antibiotics, immunosuppressives;\n* Medications containing supplement calcium or magnesium butyrate should not be taken for at least 3 months before study entry.\n* Nutraceuticals that are formulated to impact gut microbiome or immune health) and use of drugs that affect GI motility and use of any antibiotic in the last 2 months.\n* Known allergy to butyrate supplements or their derivatives such as sodium salts or hydroxy derivatives of butyrate and\u002For inactive ingredients of active and placebo soft gelatin will also be excluded.\n* Current evidence of celiac disease or late-stage cirrhosis of the liver, Giardia antigen presence, Clostridium difficile toxin in stool, tissue transglutaminase antibody, recent change in gastrointestinal medications, use of drugs that affects gastrointestinal motility, and use of any antibiotic in the last two months also will be excluded.","40 Years","70 Years",{"count":129,"type":20},120,[64],"The primary objective of this clinical trial is to determine if treatment with Butyrate formulation that consists of butyric acid as calcium and magnesium derivatives (Ca-Mg Butyrate) improves the physical function of men and women Veterans suffering from Gulf War Illness (GWI). The primary outcome measure is a change from baseline on the Short Form Health Survey 36-item (VSF-36), with respect to physical functioning and symptoms. The secondary outcome will focus on the drug's role in (a) restoring gut microbiome and virome, (b) decreasing gastrointestinal disturbances (constipation, diarrhea, pain), (c) decreasing chronic fatigue, (d) decreasing systemic inflammation, and (e) a decrease in cognitive deficits.",[133,29,134],"Gulf War Illness","Neurocognitive Dysfunction",[136,133,137,138,139,124],"SCFA","GWI","Microbiome","Butyric acid","RECRUITING","2025-10-29",{"date":143,"type":43},"2025-10-31",{"date":145,"type":43},"2024-01-15",{"date":147,"type":20},"2027-03-31",{"name":149,"class":150},"VA Office of Research and Development","FED",3,{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":21,"phases":161,"briefSummary":162,"conditions":163,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":51},"100581050","chrono-behavioral-therapy-for-chronic-fatigue-in-cancer-100581050","NCT06845267","Chrono-behavioral Therapy for Chronic Fatigue in Cancer","ChronoBT","Inclusion Criteria:\n\n1. prostate or female breast cancer survivors\n2. completed local and\u002For adjuvant cancer therapy (with the exception of hormonal therapy) ≥ 1 year previously\n3. ≥18 years of age\n4. able to speak and read Danish\n5. experiencing CRF (score ≤36 on FACT-F)\n\nExclusion Criteria:\n\n1. use of light therapy in the last year\n2. confounding underlying medical\u002Fpsychiatric disorders or use of medications associated with fatigue (e.g., a central nervous system cancer, untreated hypothyroidism, anemia, chronic fatigue syndrome, insomnia, major depression)\n3. non-cancer related factor likely to be a driver of fatigue (e.g., shift work, pregnancy, recent travel across time zones)\n4. recurrence of cancer or new cancer\n5. physical or psychological conditions that could prevent participation in intervention components\n6. use of photosensitizing medications",{"count":160,"type":20},200,[23],"Cancer-related fatigue (CRF) is a severe and persistent side effect of cancer and its treatment, affecting up to 40% of patients and significantly reducing quality of life. Recent research suggests that circadian rhythm disruption has been implicated as a possible related pathophysiological mechanism underlying CRF. Circadian rhythms are 24-hour cycles regulating physiology and behavior through environmental cues called \"zeitgebers.\" Strengthening these cues-such as light exposure, physical activity, and eating-may help reduce CRF.\n\nThis project will develop and test the optimal combination a home-based, low-burden chrono-behavioral therapy (ChronoBT) targeting these zeitgebers.",[29,164],"Cancer Survivors","2025-03-13",{"date":167,"type":43},"2025-03-14",{"date":169,"type":20},"2025-04-01",{"date":171,"type":20},"2027-11-01",{"name":173,"class":50},"Aarhus University Hospital"]